EBNA-1 Antikörper (AA 551-641)

Produktnummer ABIN1385109

Produktdetails anti-EBNA-1 Antikörper

Target: EBNA-1 (Epstein-Barr Virus Nuclear Antigen-1 (EBNA-1))

Bindungsspezifität: AA 551-641

Reaktivität: Epstein-Barr Virus (EBV), Virus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser EBNA-1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Kreuzreaktivität: Virus

Kreuzreaktivität (Details): Epstein Barr Virus

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from EBV Nuclear Antigen

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Haltbarkeit: 12 months

Details zu EBNA-1

Target: EBNA-1 (Epstein-Barr Virus Nuclear Antigen-1 (EBNA-1))

Andere Bezeichnung: EBV Nuclear Antigen (EBNA-1 Produkte)

Synonyme: EBNA-1 antikoerper, latency protein antikoerper, CeHV15gEBNA-1 antikoerper, EBNA-1 antikoerper, HHV4tp2_gp36 antikoerper

Substanzklasse: Viral Protein

Hintergrund:

Synonyms: EBNA1, EBNA-1, EBV nuclear antigen 1, Epstein Barr nuclear antigen 1, Epstein Barr virus, BKRF1, Epstein-Barr nuclear antigen 1, EBV nuclear antigen 1,

Background: Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) is the one EBV antigen that is expressed in all EBV associated malignancies. It has long been thought to go undetected by the cell mediated immune system. However, recent studies show that EBNA1 can be presented to both CD4+ and CD8+ T cells, making it a potential new target for immunotherapy of EBV related cancers.